Profile data is unavailable for this security.
About the company
Tibet Rhodiola Pharmaceutical Holding Co is a China-based company mainly engaged in the business of pharmaceutical manufacturing and pharmaceutical trading. The Company operates two segments, including the Pharmaceutical Manufacturing segment and the Pharmaceutical Trading segment. The Company mainly produces and sells capsules, biological preparations, granules, film coatings, and others. The Company's main products involve cardiovascular and cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds and other fields. The Company mainly conducts businesses within the domestic market.
- Revenue in CNY (TTM)2.72bn
- Net income in CNY981.20m
- Incorporated1999
- Employees596.00
- LocationTibet Rhodiola Pharmaceutical Holding CoNo.3, Guangzhou Road, District A, EconomTechnological Development ZoneLASA 850000ChinaCHN
- Phone+86 2 886653915
- Fax+86 2 886660740
- Websitehttps://www.xzyy.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Foyou Pharma Co Ltd | 3.42bn | 463.07m | 12.17bn | 3.64k | 25.71 | 3.22 | -- | 3.56 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.78bn | 799.61m | 12.18bn | 2.44k | 15.23 | 3.75 | -- | 3.22 | 1.41 | 1.41 | 6.67 | 5.73 | 0.711 | 1.89 | 8.06 | 1,553,625.00 | 15.08 | 11.90 | 25.52 | 18.89 | 79.26 | 74.36 | 21.21 | 16.46 | 0.9053 | -- | 0.1379 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.84bn | 546.80m | 12.36bn | 7.99k | 21.58 | 1.45 | -- | 1.26 | 0.4778 | 0.4778 | 8.61 | 7.10 | 0.623 | 3.08 | 5.32 | 1,230,310.00 | 3.48 | 2.33 | 5.81 | 4.32 | 46.64 | 41.26 | 5.58 | 3.99 | 0.6646 | 5.33 | 0.2803 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
| Shenzhen Chipscreen Biosciences Co Ltd | 850.99m | 7.28m | 12.98bn | 1.06k | 1,781.20 | 7.84 | -- | 15.25 | 0.0179 | 0.0179 | 2.09 | 4.06 | 0.2441 | 2.40 | 4.06 | 802,822.70 | 0.2089 | 0.0036 | 0.2479 | 0.0042 | 85.48 | 91.31 | 0.8557 | 0.0181 | 1.79 | -0.6319 | 0.4834 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
| Tibet Rhodiola Pharmaceutical Holding Co | 2.72bn | 981.20m | 13.45bn | 596.00 | 13.72 | 3.79 | -- | 4.95 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 9.26bn | 930.27m | 14.26bn | 11.47k | 15.33 | 1.05 | -- | 1.54 | 0.6936 | 0.6936 | 6.91 | 10.17 | 0.4703 | 2.95 | 7.65 | 807,583.30 | 5.41 | 5.14 | 7.83 | 8.21 | 33.20 | 40.86 | 11.50 | 7.82 | 2.62 | -- | 0.003 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
Data as of Feb 13 2026. Currency figures normalised to Tibet Rhodiola Pharmaceutical Holding Co's reporting currency: Chinese Yuan Renminbi CNY
3.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 2.81m | 0.87% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.53m | 0.47% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.53m | 0.47% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 1.35m | 0.42% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 911.83k | 0.28% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 395.23k | 0.12% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 353.37k | 0.11% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 336.54k | 0.10% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 262.15k | 0.08% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 234.14k | 0.07% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
